Blueprint Medicines (NASDAQ:BPMC) Price Target Raised to $105.00

Category: Finance

Barclays raised its price target for Blueprint Medicines from $75.00 to $105.00, maintaining an 'equal weight' rating. Other analysts have set higher targets, with Stephens at $140.00 and Needham at $130.00. The stock has an average rating of 'Moderate Buy' and a price target of $118.33. Recently, BPMC shares traded at $110.34, with a market cap of $6.91 billion. The company reported earnings of ($1.32) per share, exceeding estimates, and had revenue of $96.12 million for the last quarter. Insider trading activity has been noted, with significant shares sold recently.

Keywords: Blueprint Medicines, stock analysis, price target

Source: MarketBeat

Update At: 8/5/2024

Related Sources